Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin, Cisplatin, and Nivolumab in Metastatic TNBC or BRCA-Mutated Breast Cancer
NCT02393794Phase 2Active, not recruiting
- Sponsor
- Kazmira
- Start
- Jul 2015
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of romidepsin in triple-negative breast cancer (TNBC) and breast cancer (4 arms), sponsored by Kazmira. Primary endpoints: Recommended Phase II Dose at 12 months and Objective Response Rate at 24 months. Started Jul 2015; status: active, not recruiting.
02
Drugs
romidepsin
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT02393794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393794.